1965P Detection of BRCA1/2 mutations using next-generation sequencing in Asian patients with solid tumours

Abstract

BRCA1 and BRCA2 (BRCA1/2) are involved in the DNA damage response (DDR) and homologous recombination repair (HRR). PAPR inhibitors (PARPis) have shown higher therapeutic efficacy in ovarian and breast cancer patients harboring pathogenic germline or somatic BRCA1/2 (gBRCA1/2 or sBRCA1/2) mutations. Emerging evidence suggests that prostate, pancreatic and endometrial cancer patients harboring BRCA1/2 mutations could potentially benefit from the PARPis or platinum-based therapies. The aim of this study was to evaluate the prevalence of BRCA1/2 deleterious mutations in an unselected cohort of Asian patients with advanced solid tumors who will potentially benefit from PARPis.